Individually, the DAPA-HF and DELIVER studies did not test the effect of dapagliflozin on primary and secondary outcomes which led to a pooled analysis of both studies. In this touchCARDIO interview, we speak with Dr Pardeep Jhund (University of Glasgow, Glasgow, Scotland) to discuss the aims and findings of the pooled analysis of the DAPA-HF and DELIVER studies, as well as the clinical implications.
The abstract entitled ‘Pooled analysis of DAPA-HF and DELIVER’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What did the DAPA-HF and DELIVER trials teach us about the effect of dapagliflozin on outcomes in patients with heart failure, and what were their limitations? (0:18)
- What was the aims of the pooled analysis of the DAPA-HF and DELIVER studies, and what subgroups were examined? (1:29)
- What were the findings of the pooled analysis in terms of death, HF hospitalisations, MI and stroke? (2:50)
- How did ejection fraction influence the findings? (3:44)
- What is the significance of these findings for clinical practice? (5:12)
Disclosures: Pardeep Jhund is on the advisory board and a consultant for AstraZeneca, Boehringer Ingelheim and Novartis and has received grant and research support from Analog Devices, AstraZeneca and Boehringer Ingelheim. The University of Glasgow has been paid for Pardeep Jhund’s work on clinical trials by AstraZeneca, Bayer AG, Novartis and NovoNordisk.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
